Y-mAbs Therapeutics, Inc.
YMAB
$5.04
-$0.23-4.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.90M | 26.50M | 18.46M | 22.80M | 19.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.90M | 26.50M | 18.46M | 22.80M | 19.93M |
| Cost of Revenue | 3.00M | 7.84M | 2.25M | 3.01M | 2.15M |
| Gross Profit | 17.90M | 18.65M | 16.21M | 19.78M | 17.78M |
| SG&A Expenses | 12.73M | 11.87M | 13.06M | 17.40M | 11.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.52M | 30.86M | 26.31M | 32.59M | 26.84M |
| Operating Income | -5.62M | -4.36M | -7.85M | -9.79M | -6.91M |
| Income Before Tax | -5.19M | -7.54M | -6.65M | -9.15M | -6.47M |
| Income Tax Expenses | 5.00K | -752.00K | 346.00K | 100.00K | 160.00K |
| Earnings from Continuing Operations | -5.20M | -6.79M | -7.00M | -9.25M | -6.63M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.20M | -6.79M | -7.00M | -9.25M | -6.63M |
| EBIT | -5.62M | -4.36M | -7.85M | -9.79M | -6.91M |
| EBITDA | -5.55M | -4.26M | -7.73M | -9.64M | -6.75M |
| EPS Basic | -0.12 | -0.15 | -0.16 | -0.21 | -0.15 |
| Normalized Basic EPS | -0.06 | -0.08 | -0.08 | -0.13 | -0.09 |
| EPS Diluted | -0.12 | -0.15 | -0.16 | -0.21 | -0.15 |
| Normalized Diluted EPS | -0.06 | -0.08 | -0.08 | -0.13 | -0.09 |
| Average Basic Shares Outstanding | 45.10M | 44.88M | 44.63M | 44.02M | 43.78M |
| Average Diluted Shares Outstanding | 45.10M | 44.88M | 44.63M | 44.02M | 43.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |